UPSA SAS

UPSA SAS is a French company dedicated to developing and manufacturing self-medication products, medical devices, and dietary supplements aimed at alleviating minor health issues. Founded in 1935 in Paris, France, UPSA SAS specializes in self-medication products. The company has maintained a steady focus on its core offerings without notable pivots in its business strategy. UPSA operates primarily in European markets, with its headquarters located in Paris.

Isabelle Van Rycke currently serves as the CEO. UPSA specializes in the development and manufacturing of self-medication products, medical devices, and dietary supplements focusing on common minor ailments. The company offers a wide range of medications, particularly for pain relief and fever reduction, as well as treatments for respiratory conditions, digestive health, sleep disorders, and women's health. Its products are largely distributed in France, Belgium, Switzerland, and Italy, where they are recognized for their quality and commitment to being "Made in France.

"In the most recent fiscal year 2023, UPSA reported a revenue of USD 496. 01 mn and an EBITDA of USD 46. 17 mn. The company's revenue model relies on direct sales through pharmacies and retail channels and partnerships with healthcare professionals, ensuring broad accessibility of their products.